Zurich Cantonal Bank
NBIX icon

Zurich Cantonal Bank’s Neurocrine Biosciences NBIX Stock Holding History

Zurich Cantonal Bank’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.7M Buy
140,854
+46,475
+49% +$6.9M 0.05% 314
2026
Q1 		$12.4M Sell
94,379
-3,071
-3% -$407K 0.03% 444
2025
Q4 		$13.8M Buy
97,450
+30,081
+45% +$4.36M 0.03% 424
2025
Q3 		$9.46M Sell
67,369
-865
-1% -$117K 0.02% 477
2025
Q2 		$8.58M Sell
68,234
-46,531
-41% -$5.34M 0.02% 489
2025
Q1 		$12.7M Buy
114,765
+53,505
+87% +$6.78M 0.04% 401
2024
Q4 		$8.36M Buy
61,260
+360
+0.6% +$44.5K 0.02% 475
2024
Q3 		$7.02M Sell
60,900
-29,118
-32% -$3.99M 0.02% 497
2024
Q2 		$12.4M Buy
90,018
+26,195
+41% +$3.59M 0.04% 364
2024
Q1 		$8.8M Buy
63,823
+18,884
+42% +$2.58M 0.03% 430
2023
Q4 		$5.92M Buy
44,939
+25,245
+128% +$2.91M 0.02% 499
2023
Q3 		$2.22M Sell
19,694
-400
-2% -$42.1K 0.01% 679
2023
Q2 		$1.89M Buy
20,094
+5
+0% +$489 0.01% 717
2023
Q1 		$2.03M Buy
20,089
+168
+0.8% +$17.5K 0.01% 682
2022
Q4 		$2.38M Sell
19,921
-785
-4% -$91.9K 0.01% 635
2022
Q3 		$2.2M Buy
20,706
+869
+4% +$88.2K 0.01% 647
2022
Q2 		$1.93M Buy
19,837
+1,752
+10% +$162K 0.01% 681
2022
Q1 		$1.7M Sell
18,085
-91
-0.5% -$7.71K 0.01% 763
2021
Q4 		$1.55M Sell
18,176
-1,957
-10% -$180K 0.01% 824
2021
Q3 		$1.93M Sell
20,133
-83
-0.4% -$7.84K 0.01% 756
2021
Q2 		$1.97M Buy
20,216
+180
+0.9% +$17.3K 0.01% 732
2021
Q1 		$1.95M Buy
20,036
+5,057
+34% +$530K 0.01% 708
2020
Q4 		$1.44M Sell
14,979
-12,240
-45% -$1.18M 0.01% 832
2020
Q3 		$2.62M Buy
27,219
+5,012
+23% +$580K 0.02% 623
2020
Q2 		$2.71M Buy
22,207
+3,238
+17% +$358K 0.02% 541
2020
Q1 		$1.64M Buy
18,969
+1,073
+6% +$105K 0.02% 646
2019
Q4 		$1.92M Buy
17,896
+12,153
+212% +$1.27M 0.01% 677
2019
Q3 		$518K Buy
5,743
+497
+9% +$46.4K ﹤0.01% 903
2019
Q2 		$443K Hold
5,246
– – ﹤0.01% 940
2019
Q1 		$462K Sell
5,246
-870
-14% -$72.7K ﹤0.01% 910
2018
Q4 		$437K Buy
6,116
+448
+8% +$42.9K ﹤0.01% 913
2018
Q3 		$697K Buy
5,668
+159
+3% +$18K 0.01% 853
2018
Q2 		$541K Buy
5,509
+352
+7% +$31.5K ﹤0.01% 893
2018
Q1 		$428K Sell
5,157
-747
-13% -$63.1K ﹤0.01% 896
2017
Q4 		$458K Buy
5,904
+1,200
+26% +$81.9K ﹤0.01% 883
2017
Q3 		$288K Buy
4,704
+1,599
+51% +$84.4K ﹤0.01% 929
2017
Q2 		$143K Sell
3,105
-1,237
-28% -$60K ﹤0.01% 1157
2017
Q1 		$188K Sell
4,342
-3,601
-45% -$154K ﹤0.01% 1023
2016
Q4 		$307K Hold
7,943
– – ﹤0.01% 905
2016
Q3 		$402K Buy
7,943
+5,547
+232% +$276K ﹤0.01% 872
2016
Q2 		$109K Hold
2,396
– – ﹤0.01% 1108
2016
Q1 		$95K Hold
2,396
– – ﹤0.01% 1161
2015
Q4 		$136K Buy
2,396
+1,294
+117% +$65.8K ﹤0.01% 1018
2015
Q3 		$44K Buy
1,102
+730
+196% +$35.3K ﹤0.01% 1157
2015
Q2 		$18K Hold
372
– – ﹤0.01% 1130
2015
Q1 		$15K Buy
+372
New +$13.3K ﹤0.01% 1189
2014
Q3 		– Sell
-45,000
Closed -$668K – 985
2014
Q2 		$668K Hold
45,000
– – 0.02% 654
2014
Q1 		$725K Hold
45,000
– – 0.02% 600
2013
Q4 		$420K Hold
45,000
– – 0.01% 682
2013
Q3 		$509K Buy
+45,000
New +$619K 0.02% 593

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Zurich Cantonal Bank's NBIX Position: Q2 2026 in Review

Zurich Cantonal Bank increased its Neurocrine Biosciences (NBIX) stake by 49% in Q2 2026, buying an estimated $6.9M and bringing the position to 140,854 shares worth $23.7M. The position accounts for 0.05% of the portfolio, ranked #314.

Zurich Cantonal Bank first reported a position in NBIX in Q3 2013 and has held it in 50 quarters since. 771 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Zurich Cantonal Bank held 140,854 shares of Neurocrine Biosciences worth $23.7M as of Q2 2026.
  • Zurich Cantonal Bank bought 46,475 Neurocrine Biosciences shares in Q2 2026, an estimated $6.9M.
  • Neurocrine Biosciences made up 0.05% of Zurich Cantonal Bank's portfolio in Q2 2026, its #314 holding.
  • Zurich Cantonal Bank first reported a position in Neurocrine Biosciences in Q3 2013 and has held it in 50 quarters since.
  • 771 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Zurich Cantonal Bank's 13F filing for Q2 2026, filed 12 Aug 2026.